Compare Novo Nordisk A/S (NVO) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United Airlines Holdings Inc — how do they compare? Novo Nordisk A/S trades at $46.04 (market cap $207.85B), while United Airlines Holdings Inc trades at $125.15 (market cap $41.00B). The key difference: Novo Nordisk A/S is far larger — about 5.1× United Airlines Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| NVO | UAL | |
|---|---|---|
Market Cap | $207.85B | $41.00B |
Sector | Health | Industrials |
52-Week High | $63.98 | $136.11 |
52-Week Low | $35.29 | $85.21 |
Enterprise Value | $222.55B | $58.03B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
United Airlines (UAL) trades at $123.76, down 4.48% today, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a P/E of 11.83, net income margin of 5.56%, and three consecutive quarterly EPS beats. Revenue growth is steady, rising to $59.07B in 2025, with cash flow from operations at $8.43B. Recent news highlights CEO Scott Kirby's focus on innovation after merger attempts failed, while industry-wide fuel cost pressures are being managed.
Outlook remains positive with a consensus price target of $167.73, implying 35% upside. Opportunities include strong travel demand and operational efficiency, but risks involve volatile fuel prices, competitive pressures, and execution challenges. Wall Street sentiment is bullish with 66% buy ratings and no sell recommendations, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
